1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Concord Biotech Limited

Concord Biotech Limited

CONCORDBIO.NS
Concord Biotech LimitedIN flagNational Stock Exchange of India
1,304.70
INR
-0.70
- -
136.49BMarket Cap
Concord Biotech Limited
CONCORDBIO.NS
(National Stock Exchange of India)

Recent

price

1,304.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
FRC
47.62
57.74
67.72
79.4
95.4
112.78
- -
100.74
Revenue per Share
16.16
22.45
16.72
22.95
29.45
35.52
- -
24.79
Basic EPS, GAAP
-0.06
-3.57
4.97
9.65
17.18
12.75
- -
- -
Free Cash Flow per Basic Share
7.7
0.55
6.74
5.12
6.83
8.75
- -
- -
Dividend per Share
62.91
84.81
94.74
112.68
135.3
162.64
- -
182.04
Book Value per Share
73.62
94.91
105.11
123.29
145.9
173.17
- -
192.27
Tangible Book Value per Share
105
105
105
105
105
105
- -
105
Basic Weighted Avg Shares
4,982
6,041
7,084
8,306
9,981
11,798
10,464
10,549
Sales/Revenue/Turnover
39.07
50.2
33.33
36.69
38.7
39.27
29.13
27.77
Operating Margin (%)
212
275
500
540
536
544
745
745
Depreciation Expense
1,691
2,349
1,749
2,401
3,081
3,716
2,609
2,596
Net Income, GAAP
20.84
24.89
26.35
25.44
25.32
24.85
24.78
24.78
Effective Tax Rate (%)
33.95
38.89
24.69
28.9
30.87
31.5
24.93
24.6
Profit Margin (%)
4,235
5,014
4,775
5,359
7,541
9,512
10,810
10,810
Working Capital
385
579
316
64
19
6
14
14
LT Debt
7,702
9,994
11,032
12,900
15,266
18,127
20,151
20,151
Total Equity
- -
23.85
15.44
18.22
20.1
20.71
11.96
11.49
Return on Invested Capital (%)
- -
27.91
17.63
21.51
23.53
23.77
14.55
14.4
Return on Capital (%)
- -
30.4
18.63
22.13
23.75
23.85
14.46
14.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
10
- -
9
LT Borrowings
- -
- -
- -
LT Finance Leases
6
- -
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
- -
105
Market Capitalization
172,356
140,789
106,641

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10,798
- -
12,501
Cash, Cash Equivalents & STI
3,814
- -
4,188
Accounts Receivable, Net
3,968
- -
4,602
Inventories
2,763
- -
3,264
Total Current Liabilities
1,550
- -
1,691
Payables & Accruals
- -
- -
- -
ST Debt
10
- -
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.11%
11.17%
Free Cash Flow
- -
-12.76%
28.79%
Net Income, GAAP
- -
6.17%
-29.8%
Sales/Revenue/Turnover
- -
12.32%
-11.31%
Total Cash Common Dividend
- -
239.13%
22.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,948
2,623
2,408
3,001
9,981
2025
2,158
3,102
2,442
4,299
11,798
2026
2,040
2,471
2,778
3,261
10,464

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.21
7.74
7.41
- -
29.45
2025
5.7
9.15
7.26
13.42
35.52
2026
4.21
6.03
6.08
8.46
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6.83
2025
- -
- -
- -
- -
8.75
2026
- -
- -
- -
- -
- -
Similar Companies
MorphoSys AG (MOR)
Affimed N.V. (AFMD)
Versartis, Inc. (VSAR)
Moleculin Biotech, Inc. (MBRX)
KALA BIO, Inc. (0JQ2.L)
Sernova Corp. (SVA.TO)
Business
Concord Biotech Limited, an India-based R&D-driven biopharmaceutical company founded in 1984 and headquartered in Ahmedabad, India, researches, develops, manufactures, markets, and sells fermentation-based active pharmaceutical ingredients, semi-synthetic APIs, and finished dosage formulations across immunosuppressants, anti-bacterial, oncology, anti-fungal, and other therapeutic segments to customers in over 70 countries including the USA, Europe, Japan, and India. The company offers immunosuppressants such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, pimecrolimus; oncology products including temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix; anti-bacterials like mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin; anti-fungals comprising anidulafungin, caspofungin, micafungin sodium, amphotericin B, and nystatin; as well as other products such as lovastatin, pravastatin sodium, and enzymes; it also provides nephrology and critical care finished formulations along with contract research and manufacturing services in fermentation and semi-synthesis areas from three manufacturing facilities near Ahmedabad compliant with USFDA, EU-GMP, Japanese PMDA, and other global standards. In recent developments, Concord Biotech approved the acquisition of 100% equity in Celliimune Biotech in November 2025 to enter the cell and gene therapy segment and committed up to 100 million rupees to a solar power project for sustainability; the company secured key regulatory approvals including a USFDA Establishment Inspection Report and EU-GMP certification for its Dholka API facility, Russian GMP inspection completion at Dholka, NAFDAC approval for its Valthera oral solid dosage unit, and EU-GMP for its Limbasi facility, supporting expanded global market penetration amid strategic discussions with innovator firms for API supplies and second-source qualifications.